Impact of body mass index and fat distribution on sex steroid levels in endometrial carcinoma: a retrospective study.
Adipose Tissue
/ pathology
Adiposity
Aged
Aged, 80 and over
Biomarkers
Body Mass Index
Comorbidity
Endometrial Neoplasms
/ blood
Female
Gonadal Steroid Hormones
/ blood
Humans
Lipids
/ blood
Middle Aged
Neoplasm Grading
Neoplasm Staging
Obesity
/ complications
Organ Size
Retrospective Studies
Tomography, X-Ray Computed
Endometrial cancer
Estradiol
Obesity
Subcutaneous fat
Visceral fat
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
07 Jun 2019
07 Jun 2019
Historique:
received:
03
12
2018
accepted:
29
05
2019
entrez:
9
6
2019
pubmed:
9
6
2019
medline:
21
11
2019
Statut:
epublish
Résumé
Obesity is an important cause of multiple cancer types, amongst which endometrial cancer (EC). The relation between obesity and cancer is complicated and involves alterations in insulin metabolism, response to inflammation and alterations in estradiol metabolism. Visceral obesity is assumed to play the most important role in the first two mechanisms, but its role in estradiol metabolism is unclear. Therefore, this retrospective study explores the relationship of body mass index (BMI), visceral fat volume (VAV) and subcutaneous fat volume (SAV) and serum levels of sex steroids and lipids in patients with endometrial cancer. Thirty-nine postmenopausal EC patients with available BMI, blood serum and Computed Tomography (CT) scans were included. Serum was analyzed for estradiol, dehydroepiandrosterone sulfate (DHEAS), androstenedione, testosterone, cholesterol, triglycerides and high (HDL), low (LDL) and non-high density (NHDL) lipoprotein. VAV and SAV were quantified on abdominal CT scan images. Findings were interpreted using pearson correlation coefficient and linear regression with commonality analysis. Serum estradiol is moderately correlated with BMI (r = 0.62) and VAV (r = 0.58) and strongly correlated with SAV (r = 0.74) (p < 0.001 for all). SAV contributes more to estradiol levels than VAV (10.3% for SAV, 1.4% for VAV, 35.9% for SAV and VAV, p = 0.01). Other sex steroids and lipids have weak and moderate correlations with VAV or SAV. This study shows that serum estradiol is correlated with BMI and other fat-distribution measures in postmenopausal endometrial cancer patients. Subcutaneous fat tissue contributes more to the estradiol levels indicating that subcutaneous fat might be relevant in endometrial cancer carcinogenesis.
Sections du résumé
BACKGROUND
BACKGROUND
Obesity is an important cause of multiple cancer types, amongst which endometrial cancer (EC). The relation between obesity and cancer is complicated and involves alterations in insulin metabolism, response to inflammation and alterations in estradiol metabolism. Visceral obesity is assumed to play the most important role in the first two mechanisms, but its role in estradiol metabolism is unclear. Therefore, this retrospective study explores the relationship of body mass index (BMI), visceral fat volume (VAV) and subcutaneous fat volume (SAV) and serum levels of sex steroids and lipids in patients with endometrial cancer.
METHODS
METHODS
Thirty-nine postmenopausal EC patients with available BMI, blood serum and Computed Tomography (CT) scans were included. Serum was analyzed for estradiol, dehydroepiandrosterone sulfate (DHEAS), androstenedione, testosterone, cholesterol, triglycerides and high (HDL), low (LDL) and non-high density (NHDL) lipoprotein. VAV and SAV were quantified on abdominal CT scan images. Findings were interpreted using pearson correlation coefficient and linear regression with commonality analysis.
RESULTS
RESULTS
Serum estradiol is moderately correlated with BMI (r = 0.62) and VAV (r = 0.58) and strongly correlated with SAV (r = 0.74) (p < 0.001 for all). SAV contributes more to estradiol levels than VAV (10.3% for SAV, 1.4% for VAV, 35.9% for SAV and VAV, p = 0.01). Other sex steroids and lipids have weak and moderate correlations with VAV or SAV.
CONCLUSIONS
CONCLUSIONS
This study shows that serum estradiol is correlated with BMI and other fat-distribution measures in postmenopausal endometrial cancer patients. Subcutaneous fat tissue contributes more to the estradiol levels indicating that subcutaneous fat might be relevant in endometrial cancer carcinogenesis.
Identifiants
pubmed: 31174495
doi: 10.1186/s12885-019-5770-6
pii: 10.1186/s12885-019-5770-6
pmc: PMC6555924
doi:
Substances chimiques
Biomarkers
0
Gonadal Steroid Hormones
0
Lipids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
547Références
Int J Cancer. 2001 Feb 1;91(3):421-30
pubmed: 11169969
Proc Nutr Soc. 2001 Feb;60(1):81-9
pubmed: 11310427
Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1531-43
pubmed: 12496040
Singapore Med J. 2003 Dec;44(12):614-9
pubmed: 14770254
Lancet. 2005 Aug 6-12;366(9484):491-505
pubmed: 16084259
Int J Obes (Lond). 2007 Mar;31(3):500-6
pubmed: 16953256
Trends Endocrinol Metab. 2006 Oct;17(8):328-36
pubmed: 16956771
Int J Cancer. 2007 Jan 15;120(2):378-83
pubmed: 17066451
Int J Gynaecol Obstet. 2009 May;105(2):103-4
pubmed: 19367689
J Clin Endocrinol Metab. 2010 Jun;95(6):2689-98
pubmed: 20371658
Cancer Epidemiol Biomarkers Prev. 2010 Dec;19(12):3119-30
pubmed: 21030602
J Clin Endocrinol Metab. 2011 Feb;96(2):E330-9
pubmed: 21147881
Oncol Rep. 2011 Jul;26(1):65-71
pubmed: 21491090
Nat Rev Cancer. 2012 Feb 16;12(3):159-69
pubmed: 22337149
Ann Emerg Med. 1990 Dec;19(12):1462-8
pubmed: 2240762
Endocr Rev. 2012 Aug;33(4):547-94
pubmed: 22547160
Eur J Obstet Gynecol Reprod Biol. 2013 Feb;166(2):209-14
pubmed: 23176760
J Clin Oncol. 2013 Jul 10;31(20):2607-18
pubmed: 23733771
J Endocrinol Invest. 1990 May;13(5):423-6
pubmed: 2380505
J Clin Endocrinol Metab. 2013 Dec;98(12):4923-31
pubmed: 24081738
BMJ. 1989 Jan 21;298(6667):147-51
pubmed: 2538173
Nat Rev Cancer. 2015 Aug;15(8):484-98
pubmed: 26205341
Int J Gynaecol Obstet. 2015 Oct;131 Suppl 2:S96-104
pubmed: 26433681
Eur J Endocrinol. 2016 Feb;174(2):167-75
pubmed: 26553725
BMC Cancer. 2016 Mar 11;16:209
pubmed: 26968382
J Mol Endocrinol. 2016 Jul;57(1):R19-33
pubmed: 27067638
Cancer Causes Control. 2016 Jun;27(6):737-48
pubmed: 27125830
Clin Chem. 2016 Jul;62(7):930-46
pubmed: 27235445
Cancer. 2016 Sep 15;122(18):2787-98
pubmed: 27308732
Cell. 2016 Nov 3;167(4):1111-1124.e13
pubmed: 27814508
Recent Results Cancer Res. 2016;208:107-136
pubmed: 27909905
J Clin Endocrinol Metab. 2017 Dec 1;102(12):4588-4595
pubmed: 29029113
J Natl Cancer Inst. 2018 Apr 1;110(4):354-361
pubmed: 29045681
Cancer Biol Ther. 2017 Dec 2;18(12):1000-1010
pubmed: 29172956
Oncotarget. 2017 Oct 19;8(62):105184-105195
pubmed: 29285243
Gynecol Oncol. 1983 Feb;15(1):10-7
pubmed: 6822361
Obstet Gynecol. 1995 Feb;85(2):304-13
pubmed: 7824251
Mod Pathol. 1997 Oct;10(10):963-8
pubmed: 9346174